Assessment of Immuno-histochemical Expression of CD44 in Renal Tumors

Background: Cluster of differentiation 44 (CD44) is the most commonly reported immune marker of the cancer stem cells in renal cell carcinoma.Objectives: To assess the frequency of CD44 expression in renal tumors, to assess the expression of CD44 in different histological types, and to detect its as...

Full description

Saved in:
Bibliographic Details
Main Authors: Banan Mohammed, khalid Abdulfattah Khattab, Payman Salim
Format: Article
Language:English
Published: University of Anbar 2025-01-01
Series:Al-Anbar Medical Journal
Subjects:
Online Access:https://amj.uoanbar.edu.iq/article_185669_8dfa3277d44fd3b065a7b6a6baf38114.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832592022993633280
author Banan Mohammed
khalid Abdulfattah Khattab
Payman Salim
author_facet Banan Mohammed
khalid Abdulfattah Khattab
Payman Salim
author_sort Banan Mohammed
collection DOAJ
description Background: Cluster of differentiation 44 (CD44) is the most commonly reported immune marker of the cancer stem cells in renal cell carcinoma.Objectives: To assess the frequency of CD44 expression in renal tumors, to assess the expression of CD44 in different histological types, and to detect its association with variable clinicopathological parameters.Materials and methods: In this retrospective case series study, 76 cases of primary renal tumors were obtained by nephrectomy, and a study of CD44 was done by using the immunohistochemical technique.Results: The age of the patients ranged from 29-82 years with a mean of 54.8 ±11.96 with a male to female ratio of 1.05:1. Tumor size ranged from 2-17 cm with a mean of 6.2 ±3.23. Clear cell renal cell carcinoma was forming 61.83% of the cases. Among all cases, a positive CD44 expression was observed in 35 (46.05%) cases; among the malignant cases, CD44 was positive in 32 (45.71%). CD44 immunohistochemical stain showed significantly higher expression in cases with higher nuclear grade and tumor stage (P-value of 0.0376 and 0.0075, respectively). CD44 cannot differentiate between benign and malignant renal tumors.Conclusion: CD44 immune marker can be used as a prognostic factor to predict the aggressive behavior of renal tumors. It can also be used with standard prognostic markers to add prognostic information for subgrouping cases within the same grade and stage.
format Article
id doaj-art-b707dbedc2a4426fac55d4415e58173c
institution Kabale University
issn 2706-6207
2664-3154
language English
publishDate 2025-01-01
publisher University of Anbar
record_format Article
series Al-Anbar Medical Journal
spelling doaj-art-b707dbedc2a4426fac55d4415e58173c2025-01-21T21:57:32ZengUniversity of AnbarAl-Anbar Medical Journal2706-62072664-31542025-01-01211556010.33091/amj.2024.153497.1927185669Assessment of Immuno-histochemical Expression of CD44 in Renal TumorsBanan Mohammed0khalid Abdulfattah Khattab1Payman Salim2Department of Pathology, College of Medicine, University of Mosul, Mosul, Iraq.Department of Pathology, College of Medicine, University of Mosul, Mosul, Iraq.Department of Pathology, Medicolegal Institute, Erbil, Kurdistan, Iraq.Background: Cluster of differentiation 44 (CD44) is the most commonly reported immune marker of the cancer stem cells in renal cell carcinoma.Objectives: To assess the frequency of CD44 expression in renal tumors, to assess the expression of CD44 in different histological types, and to detect its association with variable clinicopathological parameters.Materials and methods: In this retrospective case series study, 76 cases of primary renal tumors were obtained by nephrectomy, and a study of CD44 was done by using the immunohistochemical technique.Results: The age of the patients ranged from 29-82 years with a mean of 54.8 ±11.96 with a male to female ratio of 1.05:1. Tumor size ranged from 2-17 cm with a mean of 6.2 ±3.23. Clear cell renal cell carcinoma was forming 61.83% of the cases. Among all cases, a positive CD44 expression was observed in 35 (46.05%) cases; among the malignant cases, CD44 was positive in 32 (45.71%). CD44 immunohistochemical stain showed significantly higher expression in cases with higher nuclear grade and tumor stage (P-value of 0.0376 and 0.0075, respectively). CD44 cannot differentiate between benign and malignant renal tumors.Conclusion: CD44 immune marker can be used as a prognostic factor to predict the aggressive behavior of renal tumors. It can also be used with standard prognostic markers to add prognostic information for subgrouping cases within the same grade and stage.https://amj.uoanbar.edu.iq/article_185669_8dfa3277d44fd3b065a7b6a6baf38114.pdfkeywords: renal cell carcinomacd44immunohistochemicalexpressionprognosis
spellingShingle Banan Mohammed
khalid Abdulfattah Khattab
Payman Salim
Assessment of Immuno-histochemical Expression of CD44 in Renal Tumors
Al-Anbar Medical Journal
keywords: renal cell carcinoma
cd44
immunohistochemical
expression
prognosis
title Assessment of Immuno-histochemical Expression of CD44 in Renal Tumors
title_full Assessment of Immuno-histochemical Expression of CD44 in Renal Tumors
title_fullStr Assessment of Immuno-histochemical Expression of CD44 in Renal Tumors
title_full_unstemmed Assessment of Immuno-histochemical Expression of CD44 in Renal Tumors
title_short Assessment of Immuno-histochemical Expression of CD44 in Renal Tumors
title_sort assessment of immuno histochemical expression of cd44 in renal tumors
topic keywords: renal cell carcinoma
cd44
immunohistochemical
expression
prognosis
url https://amj.uoanbar.edu.iq/article_185669_8dfa3277d44fd3b065a7b6a6baf38114.pdf
work_keys_str_mv AT bananmohammed assessmentofimmunohistochemicalexpressionofcd44inrenaltumors
AT khalidabdulfattahkhattab assessmentofimmunohistochemicalexpressionofcd44inrenaltumors
AT paymansalim assessmentofimmunohistochemicalexpressionofcd44inrenaltumors